Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • SEPTEMBER 2021 Issue has been successfully launched on 1 September 2021.



Briseida Dosti* and Ledjan Malaj


Objectives: The aim of this study was to evaluate the number of medicines and active ingredients for pediatric population that are authorized and marketed in Albania, for nine active ingredients which belong to medicinal products used for treatment of cardiovascular diseases. Methods: The availability of pediatric medicines and active ingredients was studied with the help of the database of the Albanian National Agency for Medicine and Medical Devices and SmPC. Selected active ingredients were categorized based on their route of administration, type of pharmaceutical form, dosage, therapeutic indication, dose capability and suitability of the pharmaceutical form for use in children. Results: Evaluation of the SmPCs of the products suggested that only two active substances are authorized for use in children; all were for solid oral forms. Approved pharmaceutical forms are as follows: 78.5% tablets, 7.4% coated tablets, 12.4% modified-release film-coated tablets and 1.7% film coated tablets. For any active ingredient wasn’t found authorized liquid formulations, which are more appropriate for use in children. Conclusion: This study shows lack of availability of pediatric medicines for selected products and shows that pediatric medicines may not be ageappropriate; even they are authorized for such use. It was shown that few medicinal products are specifically studied in children. Therefore, are needed more efforts to increase the number of drugs authorized for the pediatric groups. Even more, it is required by pharmaceutical companies to supply data on the effects of new drugs in children.

Keywords: pediatric, medicines, forms, authorized, cardiovascular.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More